These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 25982916)

  • 21. Population pharmacokinetics of teicoplanin administered by subcutaneous or intravenous route and simulation of optimal loading dose regimen.
    Cazaubon Y; Venisse N; Mimoz O; Maire P; Ducher M; Bourguignon L; Goutelle S
    J Antimicrob Chemother; 2017 Oct; 72(10):2804-2812. PubMed ID: 29091222
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pharmacokinetic and clinical studies on teicoplanin for sepsis by methicillin-cephem resistant Staphylococcus aureus in the pediatric and neonate field].
    Sunakawa K; Nonoyama M; Fujii R; Iwai N; Sakata H; Shirai M; Sato T; Kajino M; Toyonaga Y; Sano T; Naito A; Minagawa K; Niida Y; Oda T; Yokozawa M; Asanuma H; Shimura K; Fujimura M; Kitajima H; Fujinami K; Numazaki K; Fujikawa T; Kobayashi Y; Sato Y; Nishimura T; Iwata S; Tsuchihashi N; Oishi T; Matsumoto S; Motohiro T; Osawa M; Sunahara M; Shirakawa S; Nishida H; Takahashi N; Nakano R; Sai N; Iyoda K; Yoshimitsu K; Ogawa K; Okazaki T; Tsukimoto I; Motoyama O; Takada Y; Kawasaki M; Sunaoshi W; Nakamura S; Ueda Y; Kamata M; Kato T; Chiba M; Ouchi K; Sato S; Horiuchi T; Suzuki K; Shimoyama T; Masaki H; Aikyo M; Kawada M; Banba M; Furukawa S; Okada T; Yamaguchi S; Hirota O; Koizumi S; Wada H; Ohta K; Uehara T; Yukitake K; Mori T; Takakuwa S; Matsuyama K
    Jpn J Antibiot; 2002 Oct; 55(5):656-77. PubMed ID: 12532639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose.
    Pea F; Brollo L; Viale P; Pavan F; Furlanut M
    J Antimicrob Chemother; 2003 Apr; 51(4):971-5. PubMed ID: 12654757
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Variability in teicoplanin protein binding and its prediction using serum albumin concentrations.
    Yano R; Nakamura T; Tsukamoto H; Igarashi T; Goto N; Wakiya Y; Masada M
    Ther Drug Monit; 2007 Aug; 29(4):399-403. PubMed ID: 17667792
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retrospective study of teicoplanin loading regimen that rapidly achieves target 15-30 μg/mL serum trough concentration.
    Kato H; Hamada Y; Hagihara M; Hirai J; Nishiyama N; Koizumi Y; Yamagishi Y; Matsuura K; Mikamo H
    J Infect Chemother; 2016 May; 22(5):308-13. PubMed ID: 26960579
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analyses of teicoplanin concentrations from 1994 to 2006 from a UK assay service.
    Tobin CM; Lovering AM; Sweeney E; MacGowan AP
    J Antimicrob Chemother; 2010 Oct; 65(10):2155-7. PubMed ID: 20682566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of admission hyperglycemia or hypoalbuminemia on need ventilator, time ventilated, mortality, and morbidity in critically ill trauma patients.
    Safavi M; Honarmand A
    Ulus Travma Acil Cerrahi Derg; 2009 Mar; 15(2):120-9. PubMed ID: 19353313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Statistical analysis of the adverse effects of glycopeptide antibiotics, based on pharmacokinetics and toxicokinetics (PK/TK).
    Yoshida M; Matzno S; Namba H; Nishikata M; Matsuyama K
    J Infect Chemother; 2006 Jun; 12(3):114-8. PubMed ID: 16826342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Teicoplanin use in adult patients with haematological malignancy: Exploring relationships between dose, trough concentrations, efficacy and nephrotoxicity.
    Byrne CJ; Egan S; Fennell JP; O'Byrne P; Enright H; Deasy E; Ryder SA; D'Arcy DM; McHugh J
    Int J Antimicrob Agents; 2015 Oct; 46(4):406-12. PubMed ID: 26228465
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single-dose pharmacokinetics of teicoplanin during hemodialysis therapy using high-flux polysulfone membranes.
    Thalhammer F; Rosenkranz AR; Burgmann H; Graninger W; Hollenstein U; Schenk P; Thalhammer-Scherrer R; Traindl O; Hörl WH; Breyer S
    Wien Klin Wochenschr; 1997 May; 109(10):362-5. PubMed ID: 9200809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Teicoplanin physiologically based pharmacokinetic modeling offers a quantitative assessment of a theoretical influence of serum albumin and renal function on its disposition.
    Emoto C; Johnson TN; Yamada T; Yamazaki H; Fukuda T
    Eur J Clin Pharmacol; 2021 Aug; 77(8):1157-1168. PubMed ID: 33527208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic drug monitoring based on early measurements of serum teicoplanin levels in Japanese patients.
    Oda K; Kasada T; Yoshikawa M; Tanoue M; Yamashita T; Takeshita Y
    Ther Drug Monit; 2014 Jun; 36(3):401-5. PubMed ID: 24270046
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simplified dosing regimens of teicoplanin for patient groups stratified by renal function and weight using Monte Carlo simulation.
    Yamada T; Nonaka T; Yano T; Kubota T; Egashira N; Kawashiri T; Oishi R
    Int J Antimicrob Agents; 2012 Oct; 40(4):344-8. PubMed ID: 22818770
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Necessity of personalized initial loading dose calculation of teicoplanin by clinical pharmacist-examination of the utility of using systemic inflammatory response syndrome score-].
    Nakano T; Nakamura Y; Togawa A; Takata T; Ishikura H; Mishima K; Futagami K
    Yakugaku Zasshi; 2014; 134(12):1367-73. PubMed ID: 25452245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors on trough teicoplanin levels, associations between levels, efficacy and safety in patients with gram-positive infections.
    Wang T; Li N; Hu S; Xie J; Lei J; Wang Y; Zheng X; Xing J; Dong Y
    Int J Clin Pharmacol Ther; 2015 May; 53(5):356-62. PubMed ID: 25828639
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro analysis of factors affecting the continuous hemodiafiltration clearance of teicoplanin.
    Sawada M; Uchida M; Yamazaki S; Suzuki T; Suzuki T; Ishii I
    Artif Organs; 2023 Apr; 47(4):667-679. PubMed ID: 36310410
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of Teicoplanin in a Patient with Coronavirus Disease 2019 Receiving Veno-venous Extracorporeal Membrane Oxygenation.
    Hirayu N; Nakamura A; Morita T; Takasu O
    J Crit Care Med (Targu Mures); 2022 Oct; 8(4):288-291. PubMed ID: 36474610
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Teicoplanin pharmacokinetics during albumin dialysis.
    Weiler S; Falkensammer G; Seger C; Joannidis M; Bellmann R
    Artif Organs; 2011 Oct; 35(10):969-71. PubMed ID: 21501193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Teicoplanin pharmacokinetics in critically ill patients on continuous veno-venous hemofiltration.
    Bellmann R; Falkensammer G; Seger C; Weiler S; Kountchev J; Joannidis M
    Int J Clin Pharmacol Ther; 2010 Apr; 48(4):243-9. PubMed ID: 20353745
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lung and serum teicoplanin concentration after aerosol and intravenous administration in a rat model.
    Mercier E; Darrouzain F; Montharu J; Guillon A; Diot P; Paintaud G; Vecellio L
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):306-12. PubMed ID: 24320618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.